Amolyt Pharma is a clinical-stage biotechnology company developing life-changing treatments for patientssuffering from rare endocrine and metabolic diseases with a best-in-class safety profile and efficiency.Amolyt's next-gen therapeutic peptides imitate the behaviour of hormones with long-term receptor activationand possess a better physiological effect than therapies based on recombinant proteins. AZP-3601, Amolyt'slead clinical candidate, is a therapeutic peptide in development as a potential treatment forhypoparathyroidism, a rare endocrine disorder.
Visit
Triumvira Immunologics is developing a differentiated technology platform to produce autologous and allogenic T-Сell Antigen Coupler (TAC) therapeutics addressing solid tumors and blood cancer with better safety profile and efficiency in comparison with conventional CAR-T approach.In March 2021, Triumvira submitted an IND application to FDA, then started the enrollment of the referred patients into Phase I trials in collaboration with MD Anderson Cancer Center, the leading clinical trials research center in the US.
Visit
Arpeggio is developing the drug discover technology that enables direct reading of cell transcription changes and screening the activity of tens of thousands compounds in both malfunctioning and healthy cells when they are exposed to various drugs.The company has signed more than 40 strategic partnership agreements with major pharmaceutical companies, which confirms the considerable interest in the platform from the industry. Arpeggio's partners include such established global players as Pfizer, Janssen, Genentech, Novartis, etc.
Visit
Walden Biosciences is focused on developing breakthrough, disease-modifying medicines to treat kidney diseases. Walden is applying novel, multi-disciplinary approaches that directly target the kidneys to prevent damage, slow disease progression, and restore kidney function.Walden’s clinical-stage program is a humanized monoclonal antibody that inhibits suPAR, a pro-inflammatory mediator that causes podocyte dysfunction and renal disease. All of Walden’s programs offer the promise to deliver disease-modifying, breakthrough therapies.
Visit
Deka Biosciences has developed disease specific Diakines™ designed to maximize patient benefits through improved pharmacokinetics / pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Through developing a better understanding of each patient's immune response to different Diakines™, Deka hopes to maximize the impact of its Diakines™ by building specific targeted therapies for everyone.
Visit
Pria integrates health-at-home solutions into patients' individual care plans and utilizes InterSystems Health Connect Cloud to communicate with EHRs. This enables patients to seamlessly make use of remote technologies and consume in-person healthcare services, while allowing their care team and family caregivers to monitor their health remotely and engage proactively.
Visit
NASDAQ: AVIR, IPO in Oct 2020
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.Atea went public at a valuation of $1.9 billion which makes over 30x of our Series A investment back in 2014 at pre-money $10 million. The company made an exclusive partnership with Roche for the ex-US rights ahead of the IPO.
Iridia, a synthetic biology company backed by Western Digital and LifeSci Venture Partners, is developing the world's first commercially attractive, DNA-based data storage solution with a highly parallel format.The company's technology enables an array of nanomodules with the potential to store data at exceptionally high density.
Visit
NASDAQ: SNDX, IPO in Feb 2016
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. The company’s CEO is Briggs W. Morrison, a managing director of MPM Capital and a former head of R&D at AstraZeneca. Syndax pipeline includes a highly selective inhibitor of the Menin–MLL binding interaction to treat acute leukemias, axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor against chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
Visit.png){kind=logo}
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
Visit
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
VisitAmolyt Pharma is a clinical-stage biotechnology company developing life-changing treatments for patientssuffering from rare endocrine and metabolic diseases with a best-in-class safety profile and efficiency. Amolyt's next-gen therapeutic peptides imitate the behaviour of hormones with long-term receptor activationand possess a better physiological effect than therapies based on recombinant proteins. AZP-3601, Amolyt'slead clinical candidate, is a therapeutic peptide in development as a potential treatment forhypoparathyroidism, a rare endocrine disorder.
Visit site
Download ATEM's Life Sciences industry report to learn more about healthcare's accommodative liquidity and bulletproof fundamentals.
Get efficient access to one of the most exciting and private asset classes of Life Sciences innovations
of major like-minded US and Western Europe VC firms and selected private projects of successful serial entrepreneurs
from the most connected Advisory Board into investment opportunities and emerging Big Pharma needs
to optimize decision-making process and risk management
ATEM acts in strategic partnerships with the world’s leading venture firms and possesses critical mass, topnotch expertise, industrial quality diligence, and professional board-level control to identify superior technologies with healthy returns to investors
Early-stage breakthrough science managed by high-caliber serial entrepreneurs with unmatched track-record of success
Fast-growing biopharma companies with a diversified and robust pipeline and sound promise to go public or ready for M&A within one to three years
Post-revenue companies in AI drug discovery, alternative care, digital therapeutics, and robotics with potential for multi-billion growth
Projects with cure ambition, novel MoA, use of innovativedelivery platforms, and signs ofefficacy
Customizable therapeutics for people with genetic diseases that have no treatment or cure
Technologies saving lives with robust preclinical and clinical data and manageable regulatory path
Projects that let people enjoy their life experiences, with a well-understood mechanism of action
Biotech leader Amolyt Pharma has successfully raised €130 million (approx. $138M) in a Series C equity financing round, led by Sofinnova Partners and Intermediate Capital Group (ICG). New and existing investors, including Kurma Partners, Pontifax, Orbimed, and ATEM Capital, contributed to this round. Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.
read more
Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, announced that the first patient has been dosed in Phase II of its Phase I/II study TACTIC-2 (NCT04727151) investigating the safety and efficacy of autologous TAC-T cell lead asset, TAC01-HER2, in targeting HER2 in relapsed or refractory gastric and gastroesophageal junction (GEJ) tumors. TAC01-HER2 is a novel cell therapy based on genetically engineered autologous T cells expressing a T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).“This marks a significant milestone for our company, building upon the determination of the recommended Phase II dose, identifying gastric and gastroesophageal cancer patients as targets for the Phase II registration supporting study and the positive benefit we observed during the Phase I part of TACTIC-2,” said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.
read more
Deka Biosciences announced the successful completion of a Series B2 financing round, securing a total of $20 million. This financing round was led by MPM BioImpact, a specialized venture firm in the oncology field, and featured participation from notable investors, including Leaps by Bayer, Lumira Ventures, and ATEM Capital, along with the CEO, John Mumm. The capital raised through this funding will be used to advance Deka's drug development pipeline, building upon the recent FDA approval of their investigational new drug (IND) application for the evaluation of their first Diakine™.Deka's Diakines™ oncology platform is designed to harness the potential of the immune system in combating cancer. With a cumulative funding of $55 million to date, they are now progressing into the third cohort of their Phase 1 clinical trial, with promising early results indicating both safety and immune activation. Dr. John Mumm, CEO of Deka, is optimistic about the potential of DK210 to enhance the potency of the IL-2 cytokine while effectively managing its toxicity.
read more
